Inventiva Receives Recommendation From The 4th Scheduled Data Monitoring Committee Meeting Of The NATiV3 Phase III Clinical Trial With Lanifibranor In Patients With MASH/NASH
Portfolio Pulse from Benzinga Newsdesk
Inventiva received a positive recommendation from the Data Monitoring Committee to continue its Phase III clinical trial of lanifibranor for MASH/NASH without any protocol modifications. The decision was based on a review of safety data from over 900 patients, confirming the good safety profile of lanifibranor.
May 16, 2024 | 8:02 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Inventiva received a positive recommendation from the Data Monitoring Committee to continue its Phase III clinical trial of lanifibranor for MASH/NASH without any protocol modifications. The decision was based on a review of safety data from over 900 patients, confirming the good safety profile of lanifibranor.
The positive recommendation from the Data Monitoring Committee to continue the Phase III trial without modifications is a strong indicator of the safety and potential efficacy of lanifibranor. This is likely to boost investor confidence and positively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100